Next Article in Journal
Aspects of the Pathogenesis and Management of Inflammatory Bowel Diseases
Next Article in Special Issue
Tribbles Gene Expression Profiles in Colorectal Cancer
Previous Article in Journal
Development of a Motility Frailty Index in Patients with Gastroparesis
Review

Surveillance of Colorectal Cancer (CRC) in Cystic Fibrosis (CF) Patients

1
School of Specialization of Hygiene and Preventive Medicine, University of “Tor Vergata” Rome, 00161 Rome, Italy
2
Gastroenterologist, General Practitioner Limbiate, ATS Lecco-Brianza, 20812 Monza Brianza, Italy
3
School of Specialization in Anesthesia and Critical Care Medicine, Sapienza University of Rome, 00161 Rome, Italy
4
General Practitioner Barlassina, ATS Lecco-Brianza, 20825 Monza Brianza, Italy
5
Institute of Pathology, ASST Spedali Civili Brescia, 25126 Brescia, Italy
6
Endoscopy Unit, Desio Hospital, ASST-Monza, 20811 Monza Brianza, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Matjaz Rokavec
Gastrointest. Disord. 2021, 3(2), 84-95; https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3020009
Received: 8 March 2021 / Revised: 7 May 2021 / Accepted: 14 May 2021 / Published: 25 May 2021
(This article belongs to the Special Issue Therapeutic Targets for the Treatment of Colorectal Cancer)
Cystic Fibrosis (CF) is the commonest inherited genetic disorder in Caucasians due to a mutation in the gene CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), and it should be considered as an Inherited Colorectal Cancer (CRC) Syndrome. In the United States, physicians of CF Foundation established the “Developing Innovative Gastroenterology Speciality Training Program” to increase the research on CF in gastrointestinal and hepatobiliary diseases. The risk to develop a CRC is 5–10 times higher in CF patients than in the general population and even greater in CF patients receiving immunosuppressive therapy due to organ transplantation (30-fold increased risk relative to the general population). Colonoscopy should be considered the best screening for CRC in CF patients. The screening colonoscopy should be started at the age of 40 in CF patients and, if negative, a new colonoscopy should be performed every 5 years and every 3 years if adenomas are detected. For transplanted CF patients, the screening colonoscopy could be started at the age of 35, in transplanted patients at the age of 30 and, if before, at the age of 30. CF transplanted patients, between the age of 35 and 55, must repeat colonoscopy every 3 years. Our review draws attention towards the clinically relevant development of CRC in CF patients, and it may pave the way for further screenings and studies. View Full-Text
Keywords: cystic fibrosis; colorectal cancer; colonoscopy screening; colonic polyps; screening strategies cystic fibrosis; colorectal cancer; colonoscopy screening; colonic polyps; screening strategies
Show Figures

Figure 1

MDPI and ACS Style

Ingravalle, F.; Casella, G.; Ingravalle, A.; Monti, C.; De Salvatore, F.; Stillitano, D.; Villanacci, V. Surveillance of Colorectal Cancer (CRC) in Cystic Fibrosis (CF) Patients. Gastrointest. Disord. 2021, 3, 84-95. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3020009

AMA Style

Ingravalle F, Casella G, Ingravalle A, Monti C, De Salvatore F, Stillitano D, Villanacci V. Surveillance of Colorectal Cancer (CRC) in Cystic Fibrosis (CF) Patients. Gastrointestinal Disorders. 2021; 3(2):84-95. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3020009

Chicago/Turabian Style

Ingravalle, Fabio, Giovanni Casella, Adriana Ingravalle, Claudio Monti, Federica De Salvatore, Domenico Stillitano, and Vincenzo Villanacci. 2021. "Surveillance of Colorectal Cancer (CRC) in Cystic Fibrosis (CF) Patients" Gastrointestinal Disorders 3, no. 2: 84-95. https://0-doi-org.brum.beds.ac.uk/10.3390/gidisord3020009

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop